Dr. Kocour and Dr. Murray on embolization of the prostate

According to the authors, "These results support the use of Benmelstobart plus anlotinib as a new first-line treatment for advanced RCC.”

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

“There is no clear evidence that adding metformin to standard of care increases overall survival in unselected patients with metastatic hormone-sensitive disease," said Silke Gillessen, MD.

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

At a median follow-up of 9 months, the confirmed objective response rate to disitamab vedotin plus pembrolizumab was 75% in the overall population.

Patients with at least 1 NE-positive marker were shown to have a worsened rPFS and OS.